{"id":5776,"date":"2021-03-03T09:39:47","date_gmt":"2021-03-03T17:39:47","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=5776"},"modified":"2021-03-04T09:51:25","modified_gmt":"2021-03-04T17:51:25","slug":"increased-resistance-of-sars-cov-2-variant-p-1-to-antibody-neutralization","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/03\/increased-resistance-of-sars-cov-2-variant-p-1-to-antibody-neutralization\/","title":{"rendered":"Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization"},"content":{"rendered":"<ul>\n<li><i>[Pre-print, not peer-reviewed]<\/i> Reduced neutralization titers against the P.1 SARS-CoV-2 variant were found in both convalescent plasma (6.5-fold) and plasma from individuals who received an mRNA vaccine (2.2-2.8-fold). The P.1 variant completely resisted neutralization by multiple neutralizing monoclonal antibodies. Using a VSV-based SARS-CoV-2 pseudovirus with all 10 mutations of the P.1 variant, the authors note that the magnitude of the loss of activity from vaccinated individuals against this variant was modest relative to that observed with the B.1.351 variant.<span class=\"Apple-converted-space\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i>Wang et al. (Mar 2, 2021). Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. Pre-print downloaded Mar 3 from <\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.03.01.433466\">https:\/\/doi.org\/10.1101\/2021.03.01.433466<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Reduced neutralization titers against the P.1 SARS-CoV-2 variant were found in both convalescent plasma (6.5-fold) and plasma from individuals who received an mRNA vaccine (2.2-2.8-fold). The P.1 variant completely resisted neutralization by multiple neutralizing monoclonal antibodies. Using a VSV-based SARS-CoV-2 pseudovirus with all 10 mutations of the P.1 variant, the authors note&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/03\/increased-resistance-of-sars-cov-2-variant-p-1-to-antibody-neutralization\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[32,159],"topic":[31],"class_list":["post-5776","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-immunity","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=5776"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5776\/revisions"}],"predecessor-version":[{"id":5777,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5776\/revisions\/5777"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=5776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=5776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=5776"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=5776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}